Understanding how T-cell lymphomas resist treatment targeting CD47.

Dissecting mechanisms of resistance underlying CD47-SIRPα inhibition in T-cell lymphomas

NIH-funded research Massachusetts General Hospital · NIH-10873176

This study is looking into how T-cell lymphomas manage to avoid treatments that help the immune system fight cancer, with the hope of finding new ways to make these treatments work better for patients.

Quick facts

Grant typeCareer grant
Study typeNIH-funded research
Funding institutionMassachusetts General Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-10873176 on NIH RePORTER

What this research studies

This research investigates the mechanisms that allow T-cell lymphomas to evade treatment that targets the CD47-SIRPα pathway, which is crucial for immune response against tumors. By using advanced techniques like next-generation immunophenotyping and single-cell sequencing, the study aims to identify and characterize the factors that contribute to resistance in T-cell lymphomas. The goal is to uncover new therapeutic targets that could enhance the effectiveness of immunotherapies for patients with these types of cancers.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with T-cell lymphomas who may benefit from novel immunotherapy approaches.

Not a fit: Patients with other types of cancers or those who do not have T-cell lymphomas may not receive any benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with T-cell lymphomas.

How similar studies have performed: While there has been success in targeting CD47 in other malignancies, the specific mechanisms of resistance in T-cell lymphomas are still being explored, making this research both novel and critical.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.